| Product Code: ETC6186772 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Shubham Deep | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
Similar to the onchocerciasis market, the treatment market in Australia is largely defined by research, development, and export-oriented pharmaceutical activity. Australia institutions and companies play roles in formulating and testing antiparasitic treatments that support disease eradication efforts globally. There is minimal domestic consumption, but innovations in drug delivery and resistance management contribute to the country`s influence on the global stage.
The onchocerciasis treatment market in Australia is largely research- and export-oriented, with domestic market activity being minimal due to the absence of local disease prevalence. However, the market trend reflects a growing emphasis on novel therapeutic approaches like macrofilaricidal drugs and vaccine development. Partnerships with international organizations such as WHO and the Gates Foundation have encouraged Australia pharmaceutical firms to innovate treatments that can be applied globally, especially in Africa and Latin America where the disease is more prevalent.
The treatment market for Onchocerciasis in Australia faces the difficulty of importing and regulating drugs primarily developed for tropical regions. Since the disease is largely non-prevalent in Australia, accessibility and awareness are low, and drug development is often deprioritized, making it dependent on global supply chains and WHO donation programs.
Given Australia strong pharmaceutical research infrastructure, investing in onchocerciasis treatment solutions offers potential within the global pharmaceutical supply chain. Biotech firms can focus on developing novel anti-parasitic therapies and generics for global distribution. There is also an opportunity for Australia pharmaceutical companies to engage in contract manufacturing and distribution for markets in Sub-Saharan Africa and Latin America, where the disease is more prevalent, supported by international health funds and partnerships.
For onchocerciasis treatment, the TGA regulates the approval and importation of antiparasitic drugs like ivermectin. While treatment availability is limited due to non-endemicity, public health policy ensures readiness through quarantine and disease monitoring systems. Australia also collaborates internationally to fund and support research for drug development and supply in endemic regions, indirectly influencing domestic treatment strategy frameworks.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Onchocerciasis Treatment Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Onchocerciasis Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Onchocerciasis Treatment Market - Industry Life Cycle |
3.4 Australia Onchocerciasis Treatment Market - Porter's Five Forces |
3.5 Australia Onchocerciasis Treatment Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.6 Australia Onchocerciasis Treatment Market Revenues & Volume Share, By Drugs, 2021 & 2031F |
3.7 Australia Onchocerciasis Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 Australia Onchocerciasis Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
3.9 Australia Onchocerciasis Treatment Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Australia Onchocerciasis Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing awareness about onchocerciasis in Australia |
4.2.2 Rising investments in healthcare infrastructure and research for onchocerciasis treatment |
4.2.3 Growing prevalence of onchocerciasis cases in Australia |
4.3 Market Restraints |
4.3.1 Limited availability of effective treatment options for onchocerciasis |
4.3.2 High treatment costs associated with onchocerciasis management |
4.3.3 Regulatory challenges in the approval process for new onchocerciasis treatments |
5 Australia Onchocerciasis Treatment Market Trends |
6 Australia Onchocerciasis Treatment Market, By Types |
6.1 Australia Onchocerciasis Treatment Market, By Treatment |
6.1.1 Overview and Analysis |
6.1.2 Australia Onchocerciasis Treatment Market Revenues & Volume, By Treatment, 2021- 2031F |
6.1.3 Australia Onchocerciasis Treatment Market Revenues & Volume, By Medication, 2021- 2031F |
6.1.4 Australia Onchocerciasis Treatment Market Revenues & Volume, By Supportive Care, 2021- 2031F |
6.1.5 Australia Onchocerciasis Treatment Market Revenues & Volume, By Surgery, 2021- 2031F |
6.2 Australia Onchocerciasis Treatment Market, By Drugs |
6.2.1 Overview and Analysis |
6.2.2 Australia Onchocerciasis Treatment Market Revenues & Volume, By Ivermectin, 2021- 2031F |
6.2.3 Australia Onchocerciasis Treatment Market Revenues & Volume, By Moxidectin, 2021- 2031F |
6.2.4 Australia Onchocerciasis Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Onchocerciasis Treatment Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 Australia Onchocerciasis Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 Australia Onchocerciasis Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4 Australia Onchocerciasis Treatment Market, By Distribution Channel |
6.4.1 Overview and Analysis |
6.4.2 Australia Onchocerciasis Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.4.3 Australia Onchocerciasis Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
6.4.4 Australia Onchocerciasis Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5 Australia Onchocerciasis Treatment Market, By End-Users |
6.5.1 Overview and Analysis |
6.5.2 Australia Onchocerciasis Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Australia Onchocerciasis Treatment Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Australia Onchocerciasis Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Australia Onchocerciasis Treatment Market Revenues & Volume, By Others, 2021- 2031F |
7 Australia Onchocerciasis Treatment Market Import-Export Trade Statistics |
7.1 Australia Onchocerciasis Treatment Market Export to Major Countries |
7.2 Australia Onchocerciasis Treatment Market Imports from Major Countries |
8 Australia Onchocerciasis Treatment Market Key Performance Indicators |
8.1 Number of clinical trials conducted for onchocerciasis treatments in Australia |
8.2 Percentage increase in government funding for onchocerciasis research and treatment |
8.3 Rate of adoption of new onchocerciasis treatment guidelines by healthcare providers in Australia |
9 Australia Onchocerciasis Treatment Market - Opportunity Assessment |
9.1 Australia Onchocerciasis Treatment Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.2 Australia Onchocerciasis Treatment Market Opportunity Assessment, By Drugs, 2021 & 2031F |
9.3 Australia Onchocerciasis Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 Australia Onchocerciasis Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
9.5 Australia Onchocerciasis Treatment Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Australia Onchocerciasis Treatment Market - Competitive Landscape |
10.1 Australia Onchocerciasis Treatment Market Revenue Share, By Companies, 2024 |
10.2 Australia Onchocerciasis Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here